Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms CGAN study
  • Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan

    • Most Recent Events

    • 12 Sep 2023 Results of a post-hoc analysis assessing consistency of galcanezumab efficacy through the monthly dosing interval published in the Neurology and Therapy
    • 20 Oct 2022 Results of secondary analysis assessing the effect of galcanezumab on migraine headache severity, frequency of migraine-associated symptoms, and frequency of migraine headaches during menstrual periods in Japanese patients with episodic migraine, published in the Neurology and Therapy.
    • 20 Jun 2020 Results assessing quality of life questionnaire presented at the 62nd Annual Scientific Meeting of the American Headache Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top